Funding for this research was provided by:
Sunovion (None, D1050237)
Received: 5 September 2019
Accepted: 28 February 2020
First Online: 5 May 2020
Ethics approval and consent to participate
: The study analyzed in this was approved by an institutional review board (IRB) or independent ethics committee (IEC) at each study site. The names and reference numbers of the IRB/Ethics committee that approved study are listed below.All patients provided written informed consent prior to initiation of study procedures.List of IRBs by Investigator Table removed
: Not necessary (all data presented were anonymized group data).
: GWW reports receiving research support from AstraZeneca, Ayerst, Dainippon Sumitomo Pharma Co., Ltd., Eli Lilly and Co., Forest Laboratories, Inc., GlaxoSmithKline, Janssen Pharmaceuticals, Inc., Lundbeck, McNeil, Merck & Co., Inc., Novartis, Organon, Otsuka America Pharmaceutical, Inc., Pfizer Inc., Sanofi-Synthelabo, Schwabe/Ingenix, Shionogi Inc., Shire plc, Solvay Pharmaceuticals, Sunovion Pharmaceuticals Inc., Takeda Pharmaceuticals U.S.A., Inc., and Vanda Pharmaceuticals Inc.; serving on the speakers’ bureaus for Forest, Novartis, Noven Pharmaceuticals, Inc., Otsuka America Pharmaceutical, Inc., Shire plc, and Sunovion Pharmaceuticals Inc.; and serving as a consultant for Eli Lilly and Co., Forest, Novartis, Noven Pharmaceuticals, Inc., Shire plc, Shionogi Inc., and Sunovion Pharmaceuticals Inc.PMH has received honoraria for lecturing and consultancy work from Allergan, Galen, Janssen, Lundbeck, NewBridge Pharmaceuticals, Otsuka, Sunovion and Teva; and conference support from Janssen, Lundbeck, NewBridge Pharmaceuticals and Sunovion Pharmaceuticals Inc.MT, JX, DP, AP, and AL are employees of Sunovion Pharmaceuticals Inc. AL is an associate editor on the BMC Psychiatry editorial board.